Across TCGA pan-cancer cohorts, ZNF132 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNF132 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF132 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF132 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LUAD and UCEC are the cancer types where ZNF132 Mutation most reproducibly stratifies survival.